SEARCH

SEARCH BY CITATION

References

  • 1
    Petersen D, Barthels M, Schumann G, Büttner J. Concentrations of phenprocoumon in serum and serum water determined by high-performance liquid chromatography in patients on oral anticoagulant therapy. J Haemostasis 1993; 23: 8390.
  • 2
    Wilms EB, Veldkamp RF, Van Meegen E, Touw DJ. Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism. Ned Tijdschr Geneeskd 2006; 150: 20958. Dutch.
  • 3
    Van Haard PM, Engel R, Postma T. Routine clinical determination of carotene, vitamin E, vitamin A, 25-hydroxyvitamin D3 and trans-vitamin K1 in human serum by straight phase HPLC. Biomed Chromatogr 1987; 2: 7988.
  • 4
    O’Reilly RA, Aggeler PM, Hoag MS, Leong LS, Kropatkin ML. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. The first reported kindred. N Eng J Med 1964; 271: 80915.
  • 5
    Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz H-J, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 53741.
  • 6
    Bodin L, Horellou MH, Flaujac C, Loriot MA, Samama MM. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost 2005; 3: 15335.
  • 7
    Oldenburg JM, Watzka M, Rost S, Müller CR. VKORC1: molecular target of coumarins. J Thromb Haemost 2007; 5(Suppl. 1): 16.
  • 8
    Kohn MH, Pelz HJ. A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. Blood 2000; 96: 19968.
  • 9
    Rieder RJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 228593.
  • 10
    Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109: 247780.
  • 11
    SeattleSNPs. NHLBI HL66682 Program for Genomic Applications, UW-FHCRC, Seattle, WA. http://pga.gs.washington.edu. Accessed 12 December 2007.
  • 12
    D’Andrea G, D’Ambrosio RL, Di Perma P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 6459.
  • 13
    Reitsma PH, Van Der Heijden JF, Groot AP, Rosendaal FR, Büller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005; 2: 9968.
  • 14
    Kirchheiner J, Ufer M, Walter EC, Kammerer B, Kahlich R, Meisel C, Schwab M, Gleiter CH, Rane A, Roots I, Brockmöller J. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics 2004; 14: 1926.
  • 15
    Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybing G. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 2004; 60: 17382.